Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Optimizing dose-dense regimens for early-stage breast cancer

Survival of patients with high-risk early-stage breast cancer has been improved by chemotherapy administration at shorter dose intervals: 'dose-dense' therapy. Validation for this approach is provided by the AGO trial, which demonstrated the biggest survival advantage of any study of dose-dense chemotherapy to date.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Bonadonna, G. et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294, 405–410 (1976).

    CAS  Article  Google Scholar 

  2. 2

    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).

  3. 3

    De Laurentiis, M. et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26, 44–53 (2008).

    CAS  Article  Google Scholar 

  4. 4

    Norton, L. A Gompertzian model of human breast cancer growth. Cancer Res. 48, 7067–7071 (1988).

    CAS  PubMed  Google Scholar 

  5. 5

    Citron, M. L. et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 21, 1431–1439 (2003).

    CAS  Article  Google Scholar 

  6. 6

    Moebus, V. et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J. Clin. Oncol. 28, 2874–2880 (2010).

    CAS  Article  Google Scholar 

  7. 7

    Budman, D. R. et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J. Natl Cancer Inst. 90, 1205–1211 (1998).

    CAS  Article  Google Scholar 

  8. 8

    Sparano, J. A. et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N. Engl. J. Med. 358, 1663–1671 (2008).

    CAS  Article  Google Scholar 

  9. 9

    Morris, P. G. et al. Dose-dense adjuvant doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J. Clin. Oncol. 27, 6117–6123 (2009).

    CAS  Article  Google Scholar 

  10. 10

    Dang, C. et al. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J. Clin. Oncol. 28, 2982–2988 (2010).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Patrick G. Morris.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Morris, P., Hudis, C. Optimizing dose-dense regimens for early-stage breast cancer. Nat Rev Clin Oncol 7, 678–679 (2010).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing